Retigabine

D-23129, Ezogabine, Trobalt®, Potiga®
A Potent and Selective Modulator of KCNQ Channels
Cat #: R-100
Alternative Name D-23129, Ezogabine, Trobalt®, Potiga®
  • Lyophilized Powder
  • Bioassay Tested
  • Source Synthetic
    MW: 303.3
    Purity: >99% (HPLC)
    Effective concentration 0.1-100 µM.
    Chemical name Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate.
    Molecular formula C16H18FN3O2.
    CAS No.: 150812-12-7.
    Activity Retigabine is a potent and selective KCNQ (KV7, M-) channel modulator (enhancer)1-4, which is used in the clinic to treat epilepsy5. Retigabine (0.1 to 10 μM) induced a K+ current and hyperpolarized CHO cells expressing KV7.2/3 cells2 as well as other channels in the following order: KV7.3 > KV7.2/3 > KV7.2 > KV7.43. Similar effects were seen with 10 μM retigabine in oocytes expressing the KV7.2/3 heteromeric channel4.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
      • Alomone Labs Retigabine enhances KCNQ2/3 (KV7.2/7.3) currents in Xenopus oocytes.
        A. Superimposed traces (responses to 600 ms voltage steps from -50 mV to 0 mV, holding potential -100 mV,  applied every 10 sec) of KCNQ2/3 channel current responses, before (left) and during (right) application of 10 µM Retigabine (#R-100). B. Time course of current amplitude at -50 mV (holding potential -100 mV, applied every 10 sec) before, during application of 0.1 and 1 µM Retigabine (indicated by bars) and upon wash, demonstrating the current amplitude enhancement. C. I-V relations in an experiment such as in A (left before, and right, during Retigabine application). D. Voltage dependence of current increase/decrease by Retigabine.
      • The KCNQ family of voltage-gated K+ channels includes five known members: KCNQ1 to KCNQ5. Structurally, the KCNQ family belongs to the six transmembrane domain category of K+ channels. KCNQ family members can form either homomultimeric or heteromultimeric channels with different functional consequences. For example KCNQ2 and KCNQ3 heteromultimers give rise to a much larger channel current than when either protein is expressed alone. Indeed, KCNQ2/KCNQ3 heteromultimers are believed to be the molecular correlates of the so-called M current. This current is a K+ neuronal current that is strongly inhibited by the activation of the M1 subtype of the muscarinic acetylcholine receptor. Mutations in either KCNQ2 or KCNQ3 are associated with a form of epilepsy known as benign familial neonatal convulsions (BNFC)1-3.

        Retigabine is a potent and selective KCNQ (KV7, M-) channel modulator (enhancer)4-7, which is used in the clinic to treat epilepsy8. Retigabine (0.1 to 10 µM) induced a K+ current and hyperpolarized CHO cells expressing KV7.2/3 cells5 as well as other channels in the following order: KV7.3 > KV7.2/3 > KV7.2 > KV7.46. Similar effects were seen with 10 µM retigabine in oocytes expressing the KV7.2/3 heteromeric channel7.

    Target KCNQ2, KCNQ3, and KCNQ4 K+ channels
    Image & Title

    Retigabine
    Alomone Labs Retigabine activates KCNQ2/KCNQ3 channels in HEK 293 transfected cells.A. Retigabine (#R-100) activates KCNQ2/KCNQ3 channels in a concentration-dependent manner. B. Increasing concentrations of Retigabine causes a gradual hyperpolarization shift. C. Concentration-effect curve plotted as the shift in the voltage dependence of activation normalized, as a function of the concentration of Retigabine.
    Adapted from Stas, J.I. et al. (2016) Sci. Rep. 6, 35080. with permission of NATURE SPRINGER.

    Last update: 11/06/2019

    Retigabine (#R-100) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use
    Citations
    Related Products